Damora Therapeutics is trading 5.12% down now at $30.78, with broader risk-off conditions the most likely explanation as Treasury yields resumed climbing and major U.S. indexes declined.
- No credible company-specific announcement dated August 20, 2026, was identified.
- The latest disclosures were the August 10 quarterly update and August 5 initiation of the CLARITY-101 trial, both preceding the decline.
- Available coverage shows no same-day company catalyst.